This will be my first review of this tiny picocap trading at a $9.5M valuation. It’s not the first time I have done any research on them however. They did come up as a suggestion for a 2026 Wolf Pick, but they did not make the cut for reasons I cannot recall.
While the stock is up 30% over the past year it trades very choppy, down nearly 50% from their July highs. If one zooms out, Innovotech is trading at nearly the same valuations they did five years ago.
Innovotech Inc. is an established and scaling life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets.
The company announced their annual results on Tuesday evening reporting more than double 2024 revenues. The market responded positively on Wednesday sending the stock up 22%, but then were nailed to the cross by 10% on Thursday to end the short week leading into Easter weekend.
It feels like a company who struggled to hit $1M in sales five years ago that just doubled their revenue this year should be in a better share price position, and not down by 50% over the last nine months.
What’s missing? Let’s try to find out.